台灣臨床試驗主持人資料庫|TPIDB

2016-09-30 - 2018-12-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer′s Disease Dementia (The DAYBREAK Study)

Condition/Disease

Mild Alzheimer′s Disease
Test Drug

LY3314814

Participate Sites
10Sites

Terminated10Sites

黃錦章

Linkou Chang Gung Medical Foundation

Division of Neurology

2016-05-01 - 2018-09-30

Phase III

A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal junction

Condition/Disease

Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Test Drug

avelumab

Participate Sites
10Sites

Terminated9Sites

陳仁熙

Linkou Chang Gung Medical Foundation

白禮源

China Medical University Hospital-Taipei

未分科

2015-06-01 - 2018-12-31

Phase III

A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet

Condition/Disease

NSCLC
Test Drug

avelumab

Participate Sites
6Sites

Terminated6Sites

楊政達

Linkou Chang Gung Medical Foundation

2018-07-01 - 2021-12-31

Phase III

A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer

Condition/Disease

Nasopharyngeal Cancer
Test Drug

JS001

Participate Sites
8Sites

Terminated7Sites

王宏銘

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

楊慕華

Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-05-01 - 2019-12-31

Phase III

Condition/Disease
Test Drug

Participate Sites
2Sites

Terminated2Sites

黃錦章

Linkou Chang Gung Medical Foundation

Division of Neurology

2018-03-01 - 2021-06-30

Phase III

A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis

Condition/Disease

Atopic Dermatitis
Test Drug

Baricitinib (LY3009104)

Participate Sites
6Sites

Terminated6Sites

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2017-11-01 - 2019-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Condition/Disease

Moderate to Severe Atopic Dermatitis
Test Drug

Baricitinib (LY3009104)

Participate Sites
6Sites

Terminated6Sites

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2015-07-01 - 2022-12-31

Phase III

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

Condition/Disease

Hepatocellular Carcinoma
Test Drug

Ramucirumab (Cyramza)

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

楊再勝

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

黃怡翔

Taipei Veterans General Hospital

Digestive System Department

2015-09-15 - 2019-02-28

Phase II

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Condition/Disease

Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Test Drug

Ramucirumab

Participate Sites
6Sites

Terminated5Sites

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

白禮源

China Medical University Hospital-Taipei

未分科

2018-11-01 - 2019-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7

Condition/Disease

Moderate to Severe Atopic Dermatitis
Test Drug

Baricitinib (LY3009104)

Participate Sites
5Sites

Terminated5Sites

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

Search Result

List